Thursday 7 May, 2026
Objectives Population pharmacokinetic (PopPK) modeling plays a central role in model-informed drug development (MIDD); supporting decision-making throughout clinical development and…
Read morePoster: Methodology - Other topics
The Decision-Equivalence Metric (DEM) Method Based Evaluation of Biomarker Surrogacy in MASH
Thursday 7 May, 2026
Objectives: Early and reliable go/no go decisions are essential for accelerating drug development in metabolic dysfunction–associated steatohepatitis (MASH). Surrogate biomarkers…
Read moreA POTENTIAL COST OF BLOCK-DIAGONAL Ω: BIASED DOSE-RESPONSE ESTIMATES IN THE PRESENCE OF EXPOSURE-RESPONSE CONFOUNDING
Thursday 7 May, 2026
Introduction: In pharmacometrics, it is often (implicitly) assumed that the exposure-response relationship in a dose randomized study is unconfounded, at…
Read moreCOUNTING THE BIOCHEMICAL REACTION OCCURRENCES: A STATISTICAL IMPLICATION OF THE FIRST-ORDER RATE CONSTANTS IN KINETIC MODELS
Thursday 7 May, 2026
INTRODUCTION: In biochemistry and its applied sciences such as pharmacology, first-order rate constants (FORCs) are used in kinetic models to…
Read moreQUANTIFYING THE IMPACT OF LLOQ AND ULOQ CENSORING ON M3 ESTIMATION PERFORMANCE IN NONMEM
Thursday 7 May, 2026
Introduction/objectives : The analysis of pharmacokinetic (PK) clinical data is frequently complicated by censored observations, which may affect data representativeness…
Read moreBIDIRECTIONAL CONVERSION BETWEEN MRGSOLVE AND RXODE2 FOR PHARMACOMETRIC MODELS
Thursday 7 May, 2026
Objectives Pharmacometric models implemented in mrgsolve [1] and rxode2 [2] are increasingly used for simulation and exploratory analyses in R…
Read moreMETHODS FOR SUBGROUP SIMILARITY ASSESSMENT IN DOSE-RESPONSE META-ANALYSIS USING A BOOTSTRAP APPROACH
Thursday 7 May, 2026
Introduction and Objectives: Dose-response meta-analysis (DRMA) has gained considerable attention as an effective approach to synthesize the dose-response relationships reported…
Read moreChoosing the Right Exposure Metric: Power and Confounding in Exposure-Response (E-R) Models
Thursday 7 May, 2026
Introduction: As outlined by FDA guidance [1], Exposure-Response (E-R) analyses can support dosage selection and adjustments. When a single response…
Read moreR-based Bayesian workflow for ODE pharmacometrics modeling: generalized dapagliflozin PK model as a case study
Thursday 7 May, 2026
Introduction Most model-based analyses in pharmacometrics (PMx) and the associated statistical inference follow the frequentist paradigm, established in the early…
Read moreSimuRg: an R wrapper package for an AI-based pharmacometrics ecosystem
Thursday 7 May, 2026
Introduction Pharmacometrics analysis can be represented as workflow comprising multiple highly specialized steps that typically include data processing, data digitization,…
Read more